European Medicines Agency concludes that benefit-risk balance of angiotensin II receptor antagonists remains positive (EMA press release, 20 October 2011)

24 Oct 2011

The European Medicines Agency has reviewed the safety profile of angiotensin II receptor antagonists following reports of a small increased risk of new cancers. The review concludes that the benefit-risk ratio of these drugs remains favourable.